New treatment modalities in the early stage and locally advanced non-small cell lung cancer

Česká verzia

Authors: D. Krejčí ¹; F. Třebický ²; J. Fanta ³; P. Opálka ¹; N. Pauk ¹
Authors place of work: Klinika pneumologie 3. LF UK a FN Bulovka ¹; Ústav radiační onkologie, 1. LF UK a FN Bulovka ²; Chirurgická klinika 1. LF UK a FN Bulovka ³
Published in the journal: Klin Onkol 2021; 34(Supplementum 1): 43-47
Category: Review
doi: https://doi.org/10.48095/ccko2021S43

Summary

The lung cancer diagnosis is still connected with high mortality. Even the new anticancer drugs are not able to preserve long survival in the advanced lung cancer patients. Only a minority of patients is diagnosed with early or locally advanced stages. In the following review, we present interesting data regarding the treatment updates in these potentially curable patients.

Keywords:

lung cancer – early stage – treatment

Zdroje

1. Bray F, Ferlay J, Soerjomataram I et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68 (6): 394–424. doi: 10.3322/caac.21492.

2. O’Sullivan B, Brielray J, Byrd D et al. The TNM classification of malignant tumours-towards common understanding and reasonable expectations. Lancet Oncol 2017; 18 (7): 849–851. doi: 10.1016/S1470-2045 (17) 30438-2.

3. Rami-Porta R, Bolejack V, Crowley J et al. The IASLC Lung Cancer Staging Project: proposals for the revisions of the t descriptors in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol 2015; 10 (7): 990–1003. doi: 10.1097/JTO.0000000000000559.

4. Howlader N, Forjaz G, Mooradian MJ et al. The effect of advances in lung-cancer treatment on population mortality. N Engl J Med 2020; 383 (7): 640–649. doi: 10.1056/NEJMoa1916623.

5. Howington JA, Blum MG, Chang AC et al. Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143 (Suppl 5): e278S–e313S. doi: 10.1378/chest.12-2359.

6. van den Berg LL, Klinkenberg TJ, Groen HJ et al. Patterns of recurrence and survival after surgery or stereotactic radiotherapy for early stage NSCLC. J Thorac Oncol 2015; 10 (5): 826–831. doi: 10.1097/JTO.0000000000000483.

7. Timmerman R, Paulus R, Galvin J et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010; 303 (11): 1070–1076. doi: 10.1001/jama.2010.261.

8. de Koning HJ, van der Aalst CM, de Jong PA et al. Reduced lung-cancer mortality with volume ct screening in a randomized trial. N Engl J Med 2020; 382 (6): 503–513. doi: 10.1056/NEJMoa1911793.

9. Cahan WG. Radical lobectomy. J Thorac Cardiovasc Surg 1960; 39: 555–572.

10. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 1995; 60 (3): 615–622. doi: 10.1016/0003-4975 (95) 00537-u.

11. Fan J, Wang L, Jiang G-N et al. Sublobectomy versus lobectomy for stage I non-small-cell lung cancer, a meta--analysis of published studies. Ann Surg Oncol 2012; 19 (2): 661–668. doi: 10.1245/s10434-011-1931-9.

12. Schuchert MJ, et al. Oncologic outcomes after surgical resection of subcentimeter non-small cell lung cancer. Ann Thorac Surg 2011; 91 (6): 1681–1687. doi: 10.1016/j.athoracsur.2011.01.010.

13. Jeon HW, Kim Y-D, Kim KS et al. Sublobar resection versus lobectomy in solid-type, clinical stage IA, non-small cell lung cancer. World J Surg Oncol 2014; 12: 215. doi: 10.1186/1477-7819-12-215.

14. Blasberg JD, Pass HI, Donington JS. Sublobar resection: a movement from the Lung Cancer Study Group. J Thorac Oncol 2010; 5 (10): 1583–1593. doi: 10.1097/jto.0b013e3181e77604.

15. Nakamura K, Saji H, Nakajima R et al. A phase III randomized trial of lobectomy versus limited resection for small-sized peripheral non-small cell lung cancer (JCOG0802/WJOG4607L). Jpn J Clin Oncol 2010; 40 (3): 271–274. doi: 10.1093/jjco/hyp156.

16. Arriagada, R., et al., Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350 (4): 351–360. doi: 10.1056/NEJMoa031644.

17. Pignon JP, Tribodet H, Scagliotti GV et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008; 26 (21): 3552–3559. doi: 10.1200/JCO.2007.13.9030

18. Nagasaka M, Gadgeel SM. Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer. Expert Rev Anticancer Ther 2018; 18 (1): 63–70. doi: 10.1200/EDBK_175188.

19. NSCLC Meta-analysis Collaborative Group (corporate author). Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet 2014; 383 (9928): 1561–1571. doi: 10.1016/S0140-6736 (13) 62159-5.

20. Mielgo-Rubio X, Calvo V, Luna J et al. Immunotherapy moves to the early-stage setting in non-small cell lung cancer: emerging evidence and the role of biomarkers. Cancers (Basel) 2020; 12 (11): 3459. doi: 10.3390/cancers12113459.

21. Wu YL, Herbst RS, Mann H et al. ADAURA: phase III, double-blind, randomized study of osimertinib versus placebo in EGFR mutation-positive early-stage NSCLC after complete surgical resection. Clin Lung Cancer 2018; 19 (4): e533–e536. doi: 10.1016/j.cllc.2018.04.004.

22. Herbst RS, Tsuboi M, John T et al. Osimertinib as adjuvant therapy in patients with stage IB-IIIA EGFR mutation positive NSCLC after complete tumor resection: ADAURA. [online]. Available from: https: //ascopubs.org/doi/abs/10.1200/JCO.2020.38.18_suppl.LBA5.

23. Kwiatkowski DJ, Rusch VW, Chaft JE et al. Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3). Journal of Clinical Oncology 2019; 37 (15_suppl): 8503–8503. doi: 10.1200/JCO.2019.37.15_suppl.8503.

24. Provencio M, Nadal E, Insa A et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol 2020; 21 (11): 1413–1422. doi: 10.1016/S1470-2045 (20) 30453-8.

25. Potters L, Kavanagh B, Galvin JM et al. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2010; 76 (2): 326–332. doi: 10.1016/j.ijrobp.2009.09.042.

26. De Ruysscher D, Nakagawa K, Asamura H. Surgical and nonsurgical approaches to small-size nonsmall cell lung cancer. Eur Respir J 2014; 44 (2): 483–494. doi: 10.1183/09031936.00020214.

27. Solda F, Lodge M, Ashley S et al. Stereotactic radiotherapy (SABR) for the treatment of primary non-small cell lung cancer; systematic review and comparison with a surgical cohort. Radiother Oncol 2013; 109 (1): 1–7. doi: 10.1016/j.radonc.2013.09.006.

28. Widder J, Postmus D, Ubbels JF et al. Survival and quality of life after stereotactic or 3D-conformal radiotherapy for inoperable early-stage lung cancer. Int J Radiat Oncol Biol Phys 2011; 81 (4): e291–297. doi: 10.1016/j.ijrobp.2011.03.052.

29. Adebahr S, Collete S, Shash E et al. LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective. Br J Radiol 2015; 88 (1051): 20150036. doi: 10.1259/bjr.20150 036.

30. Robinson C, Hu C, Machtay M et al. P1.18-12 PACIFIC-4/RTOG 3515: phase III study of durvalumab following SBRT for unresected stage I/II, lymph-node negative NSCLC. [online]. Available from: https: //www.jto.org/article/S1556-0864 (19) 32011-8/fulltext.

31. Le Pechoux C, Pourel N, Barlesi F et al. LBA3_PR An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: primary end-point analysis of LungART (IFCT-0503, UK NCRI, SAKK) NCT00410683. [online]. Available from: https: //www.annalsofoncology.org/article/S0923-7534 (20) 42362-2/fulltext.

32. Antonia SJ, Villegas A, Daniel D et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 2018; 379 (24): 2342–2350. doi: 10.1056/NEJMoa1809697.

33. Gray JE, Villegas A, Daniel D et al. Three-year overall survival with durvalumab after chemoradiotherapy in stage III NSCLC-update from PACIFIC. J Thorac Oncol 2020; 15 (2): 288–293. doi: 10.1016/j.jtho.2019.10.002.

34. SPC Imfinzi. [online]. Dostupné z: https: //www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_cs.pdf.